CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Sulforaphane +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01228084
NCT01228084Phase 2Completed
CompareCT.gov

The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer

OHSU Knight Cancer Institute·interventional·Posted Oct 25, 2010·Updated Apr 28, 2017

In Brief

A Phase 2 clinical trial evaluating Sulforaphane, Laboratory biomarker analysis, and 1 other intervention for Adenocarcinoma of the Prostate and Recurrent Prostate Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Recurrent Prostate Cancer
CountriesUnited States
CollaboratorsThe Wayne D. Kuni and Joan E. Kuni Foundation

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 25, 2010
Enrollment StartNov 1, 2010
Primary CompletionMay 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.7 years ago

Interventions

Sulforaphanedrug

Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.

Laboratory biomarker analysisother

Correlative studies

Pharmacological studyother

Correlative studies